Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and seventh in women, accounting for 7 % of all cancers, and the third cause of cancer-related death worldwide. Nearly 90 to 95 % of all HCC occur in the context of known and often preventable risk factors, such as chronic viral hepatitis, alcohol abuse, and metabolic disorders. Although several experimental lines of research support a direct role for hepatitis C virus (HCV) in cancer promotion, cirrhosis is the main risk factor for this tumor, whereas other factors like alcohol and tobacco smoking are clearly able to accelerate HCC development. For this reason, cirrhotic patients with chronic HCV infection are subjected to abdominal ultrasound surveillance every 6 months, aimed at an early diagnosis of HCC to allow curative treatment options. Current strategies to positively impact on HCC incidence rates in HCV patients include prevention of cirrhosis development by avoiding metabolic, pharmacological, or social factors associated with accelerated progression of liver disease, or through virus eradication by interferon-based treatments. Moreover, a successful antiviral treatment has the added benefit of positively impacting on the rate of HCC development also in patients who are already cirrhotic.

Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside

Aghemo A;
2013

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and seventh in women, accounting for 7 % of all cancers, and the third cause of cancer-related death worldwide. Nearly 90 to 95 % of all HCC occur in the context of known and often preventable risk factors, such as chronic viral hepatitis, alcohol abuse, and metabolic disorders. Although several experimental lines of research support a direct role for hepatitis C virus (HCV) in cancer promotion, cirrhosis is the main risk factor for this tumor, whereas other factors like alcohol and tobacco smoking are clearly able to accelerate HCC development. For this reason, cirrhotic patients with chronic HCV infection are subjected to abdominal ultrasound surveillance every 6 months, aimed at an early diagnosis of HCC to allow curative treatment options. Current strategies to positively impact on HCC incidence rates in HCV patients include prevention of cirrhosis development by avoiding metabolic, pharmacological, or social factors associated with accelerated progression of liver disease, or through virus eradication by interferon-based treatments. Moreover, a successful antiviral treatment has the added benefit of positively impacting on the rate of HCC development also in patients who are already cirrhotic.
BCLC; HCC; HCV; Peginterferon; Sustained virological response; Antiviral Agents; Female; Genome-Wide Association Study; Hepatitis C; Chronic; Humans; Interferons; Interleukins; Liver; Liver Cirrhosis; Male; Polymorphism; Single Nucleotide; Pyrophosphatases; Carcinoma; Hepatocellular; Liver Neoplasms; Immunology; Immunology and Allergy
File in questo prodotto:
File Dimensione Formato  
Aghemo Semin Immunopathol. 2013 35 111-20.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 221.84 kB
Formato Adobe PDF
221.84 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11699/4383
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 21
social impact